Skip to content

Study · Not a test of the peptide alone · 2008

5 results

A (99m)Tc(CO)(3)-labeled pyrazolyl-alpha-melanocyte-stimulating hormone analog conjugate for melanoma targeting.

Raposinho PD, Correia JD, Alves S, Botelho MF, Santos AC, Santos I

Nuclear medicine and biology19 Nov 2007Cited by 38 (Europe PMC)

PMID18158948 (opens in a new tab)DOI10.1016/j.nucmedbio.2007.08.001 (opens in a new tab)PepBankPUB-18158948
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 01AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In melanoma-bearing C57BL6 mice, the radioconjugate showed significant tumor uptake at 4 h after injection.

    In plain wordsIn mice with melanoma, the labeled compound collected in the tumor 4 hours after injection.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableTumor uptake of the radioconjugate
    Study

    mousen: not reported in source

    Melanoma-bearing C57BL6 mice
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Tumor uptake
    4.2 %ID/g
    4 h post injection

    Source sentences

    Summary
    A significant tumor uptake [4.2+/-0.9%ID/g, at 4 h postinjection (p.i.)] was also obtained in melanoma-bearing C57BL6 mice.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  2. 02AnimalNot a test of Melanotan I (afamelanotide) aloneAnimal study (in vivo)Pharmacokinetics

    In melanoma-bearing C57BL6 mice, blocking MC1R with the agonist NDP-MSH reduced tumor uptake of the radioconjugate at 4 h after injection.

    In plain wordsIn mice with melanoma, adding NDP-MSH to block the receptor lowered tumor uptake of the labeled compound.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseTumor uptake with NDP-MSH receptor blocking
    Study

    mousen: not reported in source

    Melanoma-bearing C57BL6 mice
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Reduction in tumor uptake
    63.5%
    4 h post injection, receptor blocking with NDP-MSH

    Source sentences

    Summary
    The in vivo affinity and specificity of the radioconjugate to MC1R were demonstrated by receptor-blocking studies with the potent NDP-MSH agonist (63.5% reduction in tumor uptake at 4 h p.i.).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  3. 03LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In murine melanoma B16F1 cells, the radioconjugate showed time- and temperature-dependent internalization.

    In plain wordsIn mouse melanoma cells, the labeled compound entered the cells over time, and more so at body temperature.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableInternalization of the radioconjugate
    Study

    mousen: not reported in source

    Murine melanoma B16F1 cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Maximum internalization
    56.7%
    B16F1 cells, 4 h at 37 degrees C

    Source sentences

    Summary
    exhibited time- and temperature-dependent internalization (4 h at 37 degrees C; 56.7% maximum internalization)

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  4. 04LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cells)Activity measurement

    In murine melanoma B16F1 cells, the radioconjugate showed high cellular retention.

    In plain wordsIn mouse melanoma cells, the labeled compound stayed in the cells for hours.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableCellular retention of the radioconjugate
    Study

    mousen: not reported in source

    Murine melanoma B16F1 cells
    Outcome group
    Receptor activity and mechanism · Cancer

    Measurements

    Released from the cell
    38%
    after 5 h

    Source sentences

    Summary
    and high cellular retention (only 38% was released from the cell after 5 h)

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

  5. 05LabNot a test of Melanotan I (afamelanotide) aloneIn vitro (cell-free)Other

    A pyrazolyl-chelator conjugate of an alpha-MSH analog reacted with the technetium tricarbonyl moiety in high yield, with high specific activity and high radiochemical purity.

    In plain wordsIn lab chemistry, the labeled alpha-MSH analog formed in high yield and high purity.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableRadiolabeling yield, specific activity and radiochemical purity
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    The resulting pz-alpha-MSH analog reacted with the fac-[(99m)Tc(CO)(3)](+) moiety, giving [Ac-Nle(4),Asp(5),d-Phe(7),Lys(11)(pz-(99m)Tc(CO)(3))]alpha-MSH(4-11) in high yield, high specific activity and high radiochemical purity.

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.